Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:52 AM
Ignite Modification Date:
2025-12-25 @ 2:52 AM
NCT ID:
NCT01286233
Eligibility Criteria:
Inclusion Criteria
* The patient must have consented to participate and must have signed and dated an appropriate IRB-approved consent form that conforms to federal and institutional guidelines for the MA.32.F Study before being enrolled.
* The patient must be female.
* The patient must reside in the United States or Canada.
* The patient must be English-speaking.
* The patient must be eligible for randomization in the MA.32 treatment trial. (Participation in the MA.32 QOL study is permitted but not required.)
* The patient must not have started taking MA.32 study therapy.
* The patient must have completed primary breast radiation therapy at least two weeks prior to enrollment in MA.32.F.
Exclusion Criteria
* MA.32 study therapy has been initiated.
* Currently receiving radiation therapy or additional radiation therapy is planned for initiation after starting MA.32 study therapy.
Healthy Volunteers:
False
Sex:
FEMALE
Minimum Age:
18 Years
Maximum Age:
74 Years
Study:
NCT01286233
Study Brief:
Protocol Section:
NCT01286233